Cancer Research Institute (CRI) shared a post on LinkedIn:
“In a new clinical trial, researchers at ASCO25 described, CAR T cell therapy extended survival by 40% in patients with advanced gastric cancer.
Those who received CAR T cell therapy, results published in The Lancet Group showcase, lived an average of 7.9 months, compared with 5.5 months for those on standard care.
‘This represents a groundbreaking milestone for the field of CAR T therapies against solid tumors,’ says CRI Scientific Advisory Council member Dr. Carl June of Penn Medicine, University of Pennsylvania Health System. “
More posts featuring Cancer Research Institute